Pomide 4mg Capsule (Pomalidomide): Advanced Immunomodulatory Therapy for Multiple Myeloma Pomide 4mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Pomalidomide. It is a third-generation immunomodulatory imide drug (IMiD) specifically engineered to treat patients with relapsed or refractory Multiple Myeloma. Manufactured by Cipla Ltd., a global leader in pharmaceuticals, Pomide 4mg offers a vital therapeutic option for patients who have already undergone multiple lines of treatment, providing a targeted approach to inhibiting tumor growth and boosting the body's natural defenses. Therapeutic Indications and Clinical Usage Pomide 4mg is extensively utilized across international oncology protocols for: Relapsed and Refractory Multiple Myeloma (RRMM): Indicated for adult patients who have received at least two prior therapies, including both Lenalidomide and a proteasome inhibitor (such as Bortezomib), and have demonstrated disease progression. Combination Therapy: For maximum clinical efficacy, Pomide is typically administered in combination with low-dose Dexamethasone. Kaposi Sarcoma (KS): In certain regulatory environments, it is also used for adult patients with AIDS-related Kaposi Sarcoma after failure of highly active antiretroviral therapy (HAART). The Mechanism: How Pomide 4mg Works The active molecule, Pomalidomide, exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Tumor Cell Inhibition: It directly binds to the protein Cereblon, part of an E3 ubiquitin ligase complex. This leads to the degradation of essential transcription factors, triggering apoptosis (programmed cell death) in malignant cells. Immune System Modulation: It enhances the activity of T-cells and Natural Killer (NK) cells, significantly increasing the body's innate ability to identify and destroy cancerous cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for nourishment and growth, effectively “starving“ the malignant cells. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines like TNF-$alpha$ and IL-6, which are known to fuel the proliferation of myeloma cells in the bone marrow. Dosage and Administration Guidelines Cycle-Based Dosing: The standard dose is 4 mg orally once daily on Days 1–21 of repeated 28-day cycles. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: It can be taken with or without food but should be taken at the same time each day to maintain steady therapeutic levels. Renal/Hepatic Adjustment: Dosage adjustments may be necessary for patients with impaired renal or hepatic function, as determined by a specialist. Safety Profile and Side Effect Management Clinical management of Pomide 4 mg requires vigilant professional oversight: Hematological Monitoring: The most frequent side effects include neutropenia (low white blood cell count), anemia, and thrombocytopenia. Regular Complete Blood Counts (CBC) are mandatory. Venous Thromboembolism (VTE): There is a significantly increased risk of blood clots. Patients are often prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. Embryo-Fetal Toxicity (REMS): Pomalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. General Effects: Patients may experience fatigue, constipation, diarrhea, or shortness of breath, which are usually managed with supportive care. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C. Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules to prevent accidental exposure to the active powder. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383
